Dyskeratosis congenita and the DNA damage response

被引:28
|
作者
Kirwan, Michael [1 ]
Beswick, Richard [1 ]
Walne, Amanda J. [1 ]
Hossain, Upal [1 ]
Casimir, Colin [2 ]
Vulliamy, Tom [1 ]
Dokal, Inderjeet [1 ]
机构
[1] Queen Mary Univ London, Barts & London Childrens Hosp, Barts & London Sch Med & Dent, Ctr Paediat, London E1 2AT, England
[2] Middlesex Univ, Sch Hlth & Social Sci, London N17 8HR, England
基金
英国惠康基金;
关键词
cell cycle; DNA damage; dyskeratosis congenita; lymphocytes; telomeres; TELOMERE LENGTH; CELL-CYCLE; MUTATIONS; COMPONENT; PROLIFERATION; GENE; RNA; SHELTERIN; DIAGNOSIS; BLOCKAGE;
D O I
10.1111/j.1365-2141.2011.08679.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
P>Dyskeratosis congenita (DC) is a heterogeneous bone marrow failure disorder with known mutations in components of telomerase and telomere shelterin. Recent work in a mouse model with a dyskerin mutation has implicated an increased DNA damage response as part of the cellular pathology, while mouse models with Terc and Tert mutations displayed a normal response. To clarify how these contradictory results might apply to DC pathology in humans, we studied the cellular phenotype in primary cells from DC patients of several genetic subtypes, focussing on T lymphocytes to remain close to the haematopoietic system. We observed novel cell cycle abnormalities in conjunction with impaired growth and an increase in apoptosis. Using flow cytometry and confocal microscopy we examined induction of the DNA damage proteins gamma-H2AX and 53BP1 and the cell cycle protein TP53 (p53). We found an increase in damage foci at telomeres in lymphocytes and an increase in the basal level of DNA damage in fibroblasts, but crucially no increased response to DNA damaging agents in either cell type. As the response to induced DNA damage was normal and levels of global DNA damage were inconsistent between cell types, DNA damage may contribute differently to the pathology in different tissues.
引用
收藏
页码:634 / 643
页数:10
相关论文
共 50 条
  • [31] Dyskeratosis Congenita and Corneal Refractive Surgery
    Madeline B. Heiland
    Majid Moshirfar
    David B. Rosen
    Yasmyne C. Ronquillo
    Phillip C. Hoopes
    Ophthalmology and Therapy, 2019, 8 : 361 - 365
  • [32] Allogeneic hematopoietic stem cell transplantation for dyskeratosis congenita
    Elmahadi, Shaimaa
    Muramatsu, Hideki
    Kojima, Seiji
    CURRENT OPINION IN HEMATOLOGY, 2016, 23 (06) : 501 - 507
  • [33] Dyskeratosis Congenita and Corneal Refractive Surgery
    Heiland, Madeline B.
    Moshirfar, Majid
    Rosen, David B.
    Ronquillo, Yasmyne C.
    Hoopes, Phillip C.
    OPHTHALMOLOGY AND THERAPY, 2019, 8 (03) : 361 - 365
  • [34] The diagnosis and treatment of dyskeratosis congenita: a review
    Soledad Fernandez Garcia, M.
    Teruya-Feldstein, Julie
    JOURNAL OF BLOOD MEDICINE, 2014, 5 : 157 - 167
  • [35] Dyskeratosis congenita and telomere biology disorders
    Savage, Sharon A.
    HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2022, (01) : 637 - 648
  • [36] The genetics of dyskeratosis congenita
    Mason, Philip J.
    Bessler, Monica
    CANCER GENETICS, 2011, 204 (12) : 635 - 645
  • [37] Dyskeratosis congenita and telomerase
    Bessler, M
    Wilson, DB
    Mason, PJ
    CURRENT OPINION IN PEDIATRICS, 2004, 16 (01) : 23 - 28
  • [38] Clonal hematopoiesis in patients with dyskeratosis congenita
    Perdigones, Nieves
    Perin, Juan C.
    Schiano, Irene
    Nicholas, Peter
    Biegel, Jaclyn A.
    Mason, Philip J.
    Babushok, Daria V.
    Bessler, Monica
    AMERICAN JOURNAL OF HEMATOLOGY, 2016, 91 (12) : 1227 - 1233
  • [39] DYSKERATOSIS CONGENITA AND A RARE BRAIN ABSCESS
    Bautista Blaquier, Juan
    Ignacio Castiglione, Juan
    Delorme, Ricardo
    Wainsztein, Nestor A.
    MEDICINA-BUENOS AIRES, 2021, 81 (05) : 850 - 852
  • [40] Dyskeratosis Congenita With Corneal Limbal Insufficiency
    Aslan, Deniz
    Ozdek, Sengul
    Camurdan, Orhun
    Bideci, Aysun
    Cinaz, Peyami
    PEDIATRIC BLOOD & CANCER, 2009, 53 (01) : 95 - 97